Summary of the 1/5/14 Vertex Investor Press Release & Conference Kalydeco Growth “In 2014, further growth and achievement of the companys total 2014 net product revenue guidance for KALYDECO is dependent on completion of reimbursement discussions in Australia and Canada for eligible patients with the G551D mutation and on the potential further expansion of the […]
Approx 20% of the worldwide G551D patients are still waiting for Kalydeco in at least 13 countries.
Some of these countries cannot afford basic CF medications like Pulmozyme, so how are they going to afford $300,000+ per year per patient?
Click on the title to read more
Kalydeco recently received FDA approval for eight gating mutations: G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P and G1349D. G970R was not included.
The phase 3 gating trial showed a mean decrease in sweat chloride of -49 mmol/L & a mean increase of 10.7% FEV1. Detailed results are included in the post.
Kalydeco: Recently received FDA approval for 8 gating mutations
VX809: Phase 3 results expected mid 2014
VX661: Phase 2 F508del homozygote trial will start enrolling soon
Next gen correctors: Vertex aim to have one in trials by end of 2014
Kalydeco & R117H Trial Results:
+5.0% absolute improvement in FEV1 seen in patients aged over 18
Vertex plans to meet with the FDA in early 2014 to discuss this data and a potential FDA application
VX809 / Kalydeco:
F508del homozygote trial has completed enrollment, data expected mid 2014
Other Gating: Application submitted to FDA and EMA
R117H: Results expected this year, potential FDA application early 2014
F508del homozygotes: Phase 3 trials underway, data expected mid 2014
F508del heterozygotes: Phase 2 VX809/Kalydeco trial has commenced
Vertex are trying to treat as many patients as possible & enhance the benefit for those already on Kalydeco.
1. Kalydeco Monotherapy
2. Combination Therapy (one corrector with Kalydeco)
3. Triple Combination Therapy (two correctors with Kalydeco)